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ABSTRACT 
Objectives: To design and synthesis N-substituted (E)-4-arylidene-isoquinoline-1,3-dione derivatives as anti-inflammatory and antioxidant drug 
moieties using molecular docking as a tool. 
Methods: The structure of compounds (5a-h) was elucidated by means of FT-IR, GC-MS and NMR spectroscopy. Molecular docking was carried out 
to clarify the molecular aspects of the observed COX-inhibitory activities of the investigated compounds. DPPH radical scavenging analysis method 
was used to determine antioxidant activity and in-vitro anti-Inflammatory activity was conducted by Human Red Blood Cell (HRBC) membrane 
stabilization method utilizing Diclofenac sodium as standard. 
Results: Isoquinoline (N-substituted (E)-4-arylidene-isoquinoline-1,3-dione) derivatives were achieved using oxalic acid as the catalyst, by aldol 
condensation of the corresponding aldehydes and the corresponding N-substituted homophthalimides with a maximum yield of 92%. Ligand 
efficiency (LE) consequences being a clear indication that the action potential of the compounds 5e (-0.72) and 5d (-0.64) is high when compare 
with the standard (-0.63) for COX-1. While for COX-2, compounds 5e (-0.81) 5d (-0.79) and 5h (-0.98) were shown a remarkable ligand efficiency 
than the standard (-0.65). Anti-inflammatory and antioxidant studies on the compounds 5h<5d<5g was found best activity results. 
Conclusion: From our overall studies, it was understood that the activities of both in silico and in vitro anti-inflammatory results are coincide 
together. The p-values were significant for all the compounds 5(a-h) in both COX-1 and COX-2 activities which indicate that all the compounds have 
‘competency’ towards druggability for both anti-inflammatory and antioxidant, especially the compounds 5h<5d<5g<5e can be suggested for in vivo. 
Keywords: Antioxidant, N-arylhomophthalimides, Anti-inflammation, (E)-4arylidne-2-(4 chlorophenyl) isoquinoline 1,3-dione, Molecular Docking. 
 
INTRODUCTION 
Isoquinolines have established widespread biological activities and 
constitute a large number of naturally occurring alkaloids. Several 
isoquinoline alkaloids (berbamine, berberine, cepharanthine and 
tetrandine) were examined for anti-inflammatory activity [1, 2]. The 
presence of nitrogen bearing side chain(s) in specific positions of 
their skeletons improves binding affinity and enhances solubility 
under physiological conditions [3]. An antioxidant is a chemical that 
prevents juvenile oxidation of other chemicals. They protect key cell 
components by neutralizing the damaging effects of free radicals, 
which are normal by-products of cell metabolism [4, 5]. DPPH (2,2-
diphenyl-1-picryl-hydrazyl-hydrate) free radical method is an 
antioxidant assay based on electron-transfer that produces a violet 
solution in ethanol [6]. Inflammation is a complicated biological 
response of vascular tissue to harmful stimuli caused by injury, 
infection, environmental agents, malignancy and cellular changes 
[7]. The inflammatory process deals with the complex interplay 
between cells of the blood, the blood vessels themselves and the 
cells of the involved tissue. The process can be seen as a coordinated 
response to a large number of cells to an initial stimulus [8]. The 
cyclooxygenase-1 (COX-1) active site is prepared by a long, 
hydrophobic channel that is the site of non-steroidal anti-
inflammatory drug binding [9]. COX exists in two isotherms, COX-1 
and COX-2, which are regulated and expressed differently [10-12]. 
Rowlinson, S. W and group (2003) tested the generality of this 
binding mode by analyzing the action of a series of COX inhibitors 
against site-directed mutants of cyclooxygenase-2 (COX-2) bearing 
changes in Arg-120, Tyr-355, Tyr-348, and Ser-530 [13]. 
Determination of the crystal structure of a complex of Diclofenac 
with murine COX-2 demonstrates that Diclofenac binds to COX-2 in 
an inverted conformation with its carboxylate group hydrogen-
bonded to Tyr-385 and Ser-530. AUTODOCK predicts the binding 
affinity using one conformation of the ligand-protein complex. The 
primary method for conformations searching is a Lamarckian 
Genetic Algorithm [14] and AutoDock is shown to be an effective 
tool capable of quickly and accurately predicting binding 
conformations and binding energies of ligands with macromolecular 
targets [15, 16]. On the whole above referred basis, we directed our 
attention to the synthesis of new isoquinoline (N-substituted (E)-4-
arylideneisoquinoline-1,3-dione) derivatives 5(a–h) and biological 
studies through in silico and in vivo evaluations. 
MATERIALS AND METHODS 
All the chemicals used in the synthesis were of laboratory grade. 
Solvents and reagents were commercially available and purchased 
from sigma Aldrich and Avra synthesis. The melting points were 
observed on an Elchem digital melting point apparatus. FT-IR 
spectra were issued by SHIMADZU IR affinity 1 spectrometer with 
anhydrous KBr pellets in the range of 4000–400 cm-1. 1H NMR and 
13C NMR spectra were registered in a Bruker ADVANCE III 400 
spectrometer in CDCl3
Synthesis of N-aryl homo phthalimides (3a-c) 
 solution using tetramethylsilane (TMS) as an 
internal standard. GC-MS was analyzed in GC model Clarus 680 and 
Mass Spectrometer Clarus 600 (EI); Perkin Elmer, Inc., USA. 
A mixture of homo phthalic acid (1) and substituted anilines (2) (1:1 
ratio) in toluene and 5 mol% ZnO were amended to the suspension. 
The reaction mixture was heated under reflux condition. The 
progress of the reaction was monitored by Thin Layer 
Chromatography (TLC). After the completion of the reaction, the 
catalyst was separated by filtration. The solvent was removed under 
vacuum, and then a crude sample was purified by silica gel column 
chromatography using ethyl acetate and n-hexane mixture as an 
eluant. The obtained pale yellow solid compounds (3a-c) were 
characterized by FT-IR, GC-MS, 1H NMR and 13
 












R = 4F ,4CH3 ,4Cl
(3a-c)1 2
 
Scheme 1: General synthesis of 2-(4-flurophenyl) isoquinoline-
1, 3(2H, 4H)-dione 
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The spectral data of compounds  
3a; (2-(4-flurophenyl) isoquinoline-1,3 (2H,4H)-dione) 
Melting Point 575–577oC; IR (KBr, cm-1) 3061, 1714, 1598, 1510, 
1462, 1396, 1259, 1236, 1224, 1207, 1192, 1168, 1139, 1097, 991, 
970, 933, 840; 1H NMR (400MHz, CDCl3) 8.277-8.258 (d, J=7.6 Hz, 
1H), 7.698-7.661 (t, J=7.4Hz, 1H), 7.533-7.495 (t, J=7.6 Hz, 1H), 
7.386-7.367, (t, J=7.6 Hz, 1H), 7.218-7.202 (d, J=6.4 Hz, 1H), 4.242 (s, 
2H), 13C NMR (400 MHz, CDCl3) 169.9, 165.1, 163.7, 134.2, 134.1, 
130.4, 130.3, 129.6, 127.9, 127.4, 116.5, 116.2; GCMS for C15H10
3b; (2-(4-methylphenyl) isoquinoline-1,3 (2H,4H)-dione) 
FNO, 
calculated (M+) m/z 255.24, found 255.1507. 
Melting Point 313–315oC, Obtained 314.24oC; IR (KBr, cm-1) 2924, 
1716, 1668, 1512, 1462, 1369, 1234, 1203, 1138, 1107, 993, 929, 
862; 1H NMR (400MHz, CDCl3) 8.289-8.269 (d, J=8.0 Hz, 1H), 7.686-
7.649 (t, J=7.4Hz, 1H), 7.525-7.487 (t, J=7.6 Hz, 1H), 7.381-7.333, (t, 
J=9.6 Hz, 3H), 7.132-7.114 (d, J=7.2 Hz, 2H), 4.244 (s, 2H), 2.449 (s, 
3H); 13C NMR (400 MHz, CDCl3) 170.0, 165.1, 138.7, 134.2, 133.9, 
132.3, 130.0, 129.5, 129.5, 128.1, 127.8, 127.3, 125.5; GCMS for 
C16H13NO2
3c; (2-(4-chlorophenyl) isoquinoline-1,3 (2H,4H)-dione) 
, calculated (M+) m/z 251.28, found 255.1942. 
Melting Point 331–333oC, Obtained 332.89oC; IR (KBr, cm-1) 3120, 
2924, 1716, 1668, 1602, 1487, 1462, 1365, 1261, 1234, 1195, 1136, 
1085, 1012, 991, 931, 860; 1H NMR (400MHz, CDCl3) 8.260-8.241 (d, 
J=7.6 Hz, 1H), 7.694-7.657 (m, 1H), 7.525-7.477 (m, 3H), 7.372-
7.353, (m, J=7.6 Hz, 1H), 7.182-7.160 (d, J=8.8 Hz, 2H); 13C NMR (400 
MHz, CDCl3) 169.8, 164.9, 134.6, 134.1, 133.9, 133.5, 130.1, 129.9, 
129.6, 129.5, 127.9, 127.4, 125.3; GCMS for C15H10
Synthesis of (E)-4-arylidene isoquinoline-1,3-diones derivative 
(5a-h)  
ClNO, calculated 
(M+) m/z 271.7, found 271.1232. 
The general synthesis of compound 5a-he was achieved as shown in 
the scheme 2. N-Substituted homo phthalimide (3a-c) (0.001 mol) 
was dissolved in ethanol (10 mL) and the aromatic aldehyde (4a-c) 
(0.001 mol) followed by oxalic acid (5 mmol) was added and the 
reaction mixture refluxed for 5 h. After cooling to room temperature, 
the solid, settled on the bottom was filtered and washed with 10 ml 
of ethanol and the solvent was evaporated in a vacuum. The 
obtained product was crystallized in ethanol and the purity was 
tested by TLC. The obtained pale yellow solid compounds were 
characterized by FT-IR, GC-MS, 1H NMR, 13
 
C NMR.  
R = 4F ,
R = 4CH3 ,
 R1=  4Br ,4CH3, 4CN
R1 = 4Br , 4CH3 ,




















Scheme 2: General Synthesis of (E)-4-arylidene isoquinoline-
1,3-diones derivative (5a-h) 
 
The spectral data of compounds (5a-h) 
(E)-4-(4-bromobenzylidene)-2-(4-fluorophenyl) isoquinoline-
1,3(2H,4H)-dione (5a) 
Melting Point 490-492oC, Obtained 491.55oC; IR (KBr, cm-1) 1712, 
1668, 1600, 1506, 1402, 1357, 1292, 1240, 1190,1070, 1008, 927, 
867; 1H NMR (400MHz, CDCl3) 8.299-8.279 (d, J=8.0 Hz, 1H), 8.136 
(s, 1H) 7.640-7.620 (d, J=8.0 Hz, 1H), 7.577-7.558, (d, J=7.6 Hz, 2H), 
7.514-7.477 (t, J=7.4 Hz, 1H) 7.438-7.370 (m, 3H), 7.289-7.207 (m, 
4H); 13C NMR (400 MHz, CDCl3) 165.8, 164.20, 161.3, 143.2, 134.1, 
133.8, 132.4, 131.9, 130.4, 130.4, 130.2, 129.6, 129.2, 127.2, 126.2, 
125.9, 124.1, 116.2; GCMS for C22H13BrFNO2
(E)-4-(4-methylbenzylidene)-2-(4-fluorophenyl) isoquinoline-
1,3 (2H,4H)-dione (5b) 
, calculated (M+) m/z 
422.25, found 422.1040. 
Melting Point 442-444oC, Obtained 443.02oC; IR (KBr, cm-1) 3086, 
1710, 1666, 1593, 1508, 1458, 1359, 1240, 1217, 1190,1153, 1126, 
1091, 1002, 813; 1H NMR (400MHz, CDCl3) 8.291-8.272 (d, J=7.6 Hz, 
1H), 8.234 (s, 1H) 7.776-7.756 (d, J=8.0 Hz, 1H), 7.484-7.397 (m, 
4H), 7.378-7.213 (m, 6H), 2.444 (s, 3H); 13C NMR (400 MHz, CDCl3) 
166.1, 164.4, 163.7, 145.2, 140.3, 132.5, 132.2, 130.4, 130.3, 129.7, 




, calculated (M+) m/z 357.38, found 357.1517. 
Melting Point 507-509oC, Obtained 508.01oC; IR (KBr, cm-1) 3027, 
2211, 1714, 1586, 1475, 1375, 1351, 1251, 121-47, 1186,1174, 
1075, 1011, 986, 862; 1H NMR (400MHz, CDCl3) 8.325-8.306 (d, 
J=7.6 Hz, 1H), 8.182 (s, 1H) 7.746-7.727 (d, J=7.6 Hz, 2H), 7.606-
7.588 (d, J=7.2 Hz, 2H) 7.546-7.515 (t, J=6.2 Hz, 1H), 7.427 (s, 2H), 
7.284-7.219 (m, 4H); 13C NMR (400 MHz, CDCl3) 165.5, 163.9, 163.7, 
141.5, 140.2, 132.8, 131.2, 130.3, 130.2, 129.8, 129.3, 128.1, 127.2, 
126.1, 118.2, 116.54, 116.3, 113.0; GCMS for C23H13FN2O2
(E)-4-(4-bromobenzylidene)-2-(4-methylphenyl) isoquinoline-
1,3 (2H,4H)-dione (5d) 
, 
calculated (M+) m/z 368.36, found 368.0132. 
Melting Point 501-503oC, Obtained 502.23oC; IR (KBr, cm-1) 3078, 
1710, 1668, 1602, 1446, 1349, 1227, 1182, 1127, 966 812; 1H NMR 
(400MHz, CDCl3) 8.306-8.287 (d, J=7.6 Hz, 1H), 8.135 (s, 1H) 7.620-
7.558 (m, 3H), 7.502-7.468 (t, J=6.8 Hz, 1H), 7.424-7.348 (m, 5H), 
7.182-7.164 (d, J=7.2 Hz, 2H), 2.444 (s, 3H); 13C NMR (400 MHz, 
CDCl3) 165.9, 164.3, 142.8, 138.6, 134.2, 132.6, 132.3, 131.9, 131.1, 




, calculated (M+) m/z 418.28, found 418.1310. 
Melting Point 442–444 oC, Obtained 453.7 oC; IR (KBr, cm-1) 2970, 
1735, 1707, 1664, 1595, 1510, 1446, 1357, 1236, 1217, 1193,1178, 
1091, 1002, 817; 1H NMR (400MHz, CDCl3) 8.302-8.283 (d, J=7.6 Hz, 
1H), 8.236 (s, 1H) 7.761-7.742 (d, J=7.6 Hz, 1H), 7.476-7.354 (m, 
6H), 7.246-7.181 (m, 4H), 2.466 (s, 3H), 2.446 (s, 3H); 13C NMR (400 
MHz, CDCl3) 166.23, 164.5, 144.9, 140.1, 138.5, 132.9, 132.5, 132.4, 




, calculated (M+) m/z 353.41, found 353.1938. 
Melting Point 520–522 oC, Obtained 520.88 oC; IR (KBr, cm-1) 3095, 
1710, 1668, 1602, 1583, 1460, 1355, 1234, 1182,1134, 1006, 827; 
1H NMR (400MHz, CDCl3) 8.295-8.275 (d, J=8.0 Hz, 1H), 8.135 (s, 
1H) 7.637-7.617 (d, J=8.0 Hz, 1H), 7.579-7.559 (d, J=8.0 Hz, 2H), 
7.529-7.478 (m, 3H), 7.441-7.369 (m, 3H), 7.245-7.224 (d, J=8.0 Hz, 
2H); 13C NMR (400 MHz, CDCl3) 165.6, 164.0, 143.2, 134.7, 134.1, 
133.7, 132.8, 132.3, 131.8, 130.3, 129.9, 129.6, 129.6, 129.4, 127.2, 
126.1, 125.9, 124.0; GCMS for C23H16FNO2
(E)-4-(4-methylbenzylidene)-2-(4-chlorophenyl) isoquinoline-
1,3(2H,4H)-dione (5g) 
, calculated (M+) m/z 
438.7, found 439.1080. 
Melting Point 471–473oC, Obtained 472.35oC; IR (KBr, cm-1) 2970, 
1737, 1710, 1664, 1593, 1490, 1446, 1357, 1274, 1234, 1193, 1178, 
1085, 1001, 923, 923, 817; 1H NMR (400MHz, CDCl3) 8.281-8.262 (d, 
J=7.6 Hz, 1H), 8.227 (s, 1H) 7.771-7.752 (d, J=7.6Hz, 1H), 7.529-
7.376 (m, 6H), 7.289-7.223, (m, 4H); 13C NMR (400 MHz, CDCl3) 
165.9, 164.2, 145.3, 140.3, 134.3, 134.5, 133.9, 132.6, 132.5, 132.1, 




, calculated (M+) m/z 373.83, found 373.1310. 
Melting Point 536–538oC, Obtained 537.34oC; IR (KBr, cm-1) 3074, 
2227, 1714, 1666, 1597, 1490, 1375, 1251, 1236, 1186, 1174, 1087, 
Arumugam et al. 
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1014, 974, 862; 1H NMR (400MHz, CDCl3) 8.312-8.293 (d, J=7.6 Hz, 
1H), 8.175 (s, 1H) 7.598-7.578 (d, J=8.0Hz, 2H), 7.547-7.494 (m, 3H), 
7.445-7.412 (m, 2H), 7.251-7.216 (m, 2H); 13C NMR (400 MHz, 
CDCl3) 165.3, 163.8, 141.6, 140.2, 134.8, 133.0, 132.8, 131.2, 129.9, 
129.9, 129.8, 129.3, 127.9, 127., 126.1, 118.2, 113.1; GCMS for 
C23H13ClN2O2
All biological in vitro and in silico experiments results were 
expressed as percentage decrease with respect to control values and 
compared by one-way ANOVA with Dunnett’s post test was 
performed. GraphPad Prism version 6.07 for Windows, GraphPad 
Software, San Diego California USA, 
, calculated (M+) m/z 384.81, found 384.2451. 
Statistical analysis  
www. graphpad. com was used 
for statistical analysis. A difference was considered statistically 
significant if p≤0.05.  The 50% inhibitory concentration (IC50
Docking studies were performed in order to get more insight into 
the binding mode of the compounds. Docking studies were 
conducted by using Autodock version 4.2.6 and Autodock Tools 
(ADT) version 1.5.6. and the Arguslab version 4.0.1. The structures 
of compounds 5(a-h) and standard (Diclofenac–Fig.1) were 
generated as ligands using Chemdraw ultra 10.0 version of 
Cambridge University. Their 3D atomic coordinates were created 
utilizing the ACD/labs–Chemsketch 12.0 software. Compound 
geometries were cleaned and generated as the corresponding pdb. 
files using the Argus lab software. The three-dimensional structure 
of human COX–1 (PDB id: 1CQE) and COX-2 (PDB id: 6COX) enzymes 
were retrieved from the protein data bank (PDB) (Source: www. 
rcsb. org/pdb/). The proteins and ligands in the docking tests were 
treated using the united-atom approximation and only polar 
hydrogens were added to the protein, and Kollman united atom 
partial charges were assigned. Unless stated otherwise, all waters 
were removed [17]. The pdbqt files for protein and ligands 
preparation and grid box creation were completed using Graphical 
User Interface program AutoDock Tools (ADT). AutoGrid was used 
for the preparation of the grid map using a grid box. The grid size 
was set to 66 × 66 × 66 xyz points with grid spacing of 0.385 Å and 
grid center was designated at dimensions (x, y, and z): 1.085, 0.864 
and 2.564. The ligands 5(a-h) were docked into the active sites of 
COX-1 and COX-2. The results less than 2.0 Å in positional root-
mean-square deviation (RMSD) was clustered together and 
represented by the result with the most favorable free energy of 
binding. The docked poses with Lowest Binding Energy (LBE), 
Hydrogen bond, π-π interaction and π-cation interaction results 
were recorded (table 1&2) and validated.  
) was 
calculated from the dose-response curve obtained by plotting 
percentage inhibition versus concentrations. 
Molecular docking studies 
In-vitro anti-inflammatory activity 
In-vitro Anti-Inflammatory activity was carried out by Human Red 
Blood Cell (HRBC) membrane stabilization method [18] using 
Diclofenac sodium as standard. 5 ml of human blood was collected 
from a healthy volunteer and mixed with equal volume of sterilized 
Alsever solution. The blood was subsequently centrifuged at 3000 
rpm and packed cells were washed with isosaline 0.85% (pH 7.21) 
and a 10% v/v suspension was made with isosaline. Drug 
concentrations of 50, 100, 150, 200 μg/ml were prepared. The 
desired concentration of the drug was combined with 1 ml 
phosphate buffer (0.15 M, pH 7.4), 2 ml hypo saline (0.36%) and 0.5 
ml HRBC suspension. Instead of hypo saline 2 ml distilled water 
served as the control. Hemoglobin content in the supernatant 
solution obtained after centrifugation was estimated at 560 nm. The 
percentage haemolysis was calculated by assuming the haemolysis 
produced in the presence of distilled water at 100%. The percentage 
of HRBC membrane stabilization was calculated and tabulated (table 
4) using the following formula: 
% Inhibition of haemolysis = 100 x [(OD1-OD2)/OD1] 
Where OD2 = optical density of sample OD1 = optical density of 
control.  
DPPH radical scavenging analysis of antioxidant activity 
The antioxidant activity was evaluated in terms of hydrogen 
donating or radical scavenging ability using the stable radical 
DPPH. Experiments were performed according to the method of 
Gardeli, C [19]. 4.3 mg of DPPH (1, 1-Diphenyl–2-picrylhydrazyl) is 
mixed with 3.3 ml methanol. It is shielded from light by covering 
the test tubes with aluminum foil. 150 µl of DPPH solution were 
added to 3 ml methanol and absorbance was noted at 517 nm as 
control. 10-200 µl of different concentrations of test compounds 
and standard compound were taken and the volume was made up 
to 200 µl using methanol. The samples were then diluted with 
methanol up to 3 ml and to each 150 µl DPPH was added. 
Absorbance was taken after 15 min at 517 nm using methanol as 
blank on the UV-visible spectrometer. The scavenging activity 
percentage (AA %) was determined according to Mensor [20]. The 
amount of sample necessary to decrease the observance of DPPH 
by 50% (IC 50) was calculated graphically for the test compounds 
in five different concentrations. The percentage inhibition of the 
DPPH radical was calculated and tabulated (table 5) using the 
following formula:  
AA%= 100-[(A2–A1) x 100]/A
Where A2 = absorbance of the sample, the A1= absorbance of blank 
and A0= absorbance of control 
0 
 
Table 1: Chemical yield of the new compounds 5(a-h) via Scheme 1 and 2 
Compound 3 (a-c) Compound 4 (a-c) Conditions Reaction time Compounds Yield % 




5 H 5a, 5d, 5f 92, 89, 
90 




5 H 5b, 5e, 5g 90, 91, 
90 
C15H10 4-formylbenzonitrile (0.001 mol), Ethanol (10 mL), Oxalic acid (5 mmol) ClNO (0.001 
mol) 
5 H 5c, 5h 88, 86 
 
RESULTS AND DISCUSSION 
Chemistry 
Synthesis of intermediate and target compounds was accomplished 
according to the steps depicted in scheme 1 and scheme 2. The (E)-
4-arylidene isoquinoline-1,3-diones derivatives 5(a–h) were 
obtained by condensation of aromatic aldehydes 3(a-c) with N-
substituted homo phthalimides 4(a-c) in ethanol using oxalic acid as 
catalyst. All synthesized derivatives appeared as yellow solid and the 
chemical yield of the new compounds 5(a-h) was calculated and 
tabulated (table 1). (See figure-1 in supplementary file for 
synthesized structures of the compounds 5 (a-h)) 
Molecular docking analysis 
Dog site [21] web server was employed to detect the binding pocket of 
1CQE and 6COX. Diclofenac was used as the standard (fig. 1) for docking 
analysis. The results of the molecular docking analysis indicate that all 
the compounds were more selective towards COX-2 than COX-1. The 
expected binding free energy for COX-2 was found between-31.94 and-
6.03 kcal/mol and the COX-1 showed the binding free energy between-
18.77 and-0.56 kcal/mol. These free energy values indicating that the 
newly synthesized compounds had shown a fortunate selectivity 
towards COX-2 instead of COX-1. The best-squared correlation 
coefficient was observed (r2=-0. 91) between binding affinities (Y-axis) 
and experimental values for COX-2, 6COX (fig. 2). 
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Fig. 1: Molecular structure of the standard (Diclofenac) 
 
The 2D view of protein–ligand interactions of the best poses 
generated by COX-1 and COX-2 studied routines are shown in fig. 3. 
All the top docked poses generated (table 1&2) by each docking 
routine exhibited well-established bonds with one or more amino 
acids in the binding pocket of 1CQE and 6COX. Especially with three 
hydrogen bonds were evolved with HIS207 for 1CQE and four 
hydrogen bonds evolved with HIS388 for 6COX. Different sets of 
hydrogen bonding interactions with polar side chain residues of 
ASN515, ARG83, GLY289, HIS207, ILE137, SER579, THR94 and 
TYR136 were observed at distances within 2.9 Å. For 1CQE and 
6COX almost all ligands (5a-h) were shown π-π interactions show 
the drug efficiency of the compounds. 
 
 
Fig. 2: Squared correlation coefficient comparison for COX1 
(1CQE) and COX2 (6COX) 
 





LE AA# π-π interaction  residue H-bond Å π-cation 
interaction 




5b -8.62 -0.32 ARG83: H H12 1.826Å HIS90, PHE381 ARG120 






5d -16.03 -0.64 ILE137: HN 1 2.159Å,  PHE210 NF 
5e -18.77 -0.72 HIS207: HE2 1 2.159Å PHE210 NF 
5f -8.16 -0.29 THR94: HG1 1 1.937Å HIS207 NF 
5g -12.02 -0.42 PHE580: HN1 2.158Å HIS388 NF 
5h -8.32 -0.31 HIS207: HE2 1, GLN289: HE22 1 1.856Å, 
1.855Å 
HIS388, PHE404  
NF 





PHE209, PHE381 NF 
#
 
Amino Acid, * Std-Standard (Diclofenac), **NF-Not Formed 
Table 3: Molecular docking scores of 5(a-h) with COX-2 (6COX) 
Compounds LBE 
(Kcal/mol)  
LE AA# residue H-bond Å π-π interaction π-cation interaction 
5a -6.03 -0.22 HIS388: HE2 1 2.215Å HIS207, HIS214, PHE198, THR383 ARG120 
5b -7.25 -0.25 NF NF HOS90, PHE381 ARG120 
5c -7.03 -0.28 HIS388: HE2 1 1.593Å HIS388, PHE404 NF** 
5d -25.14 -0.79 TYR385:O 1, GLN203:O 1 2.677Å, Invisible PHE210 NF 
5e -26.69 -0.81 HIS388: HE2 1 2.146Å PHE210 NF 
5f -9.35 -0.42 HIS388: HE2 1 1.745Å HIS207 NF 
5g -8.56 -0.34 HIS388: HE2 1 2.129Å HIS388 NF 
5h -31.94 -0.98 MET522:O 2.433Å TRP387, TYR348, TYR385 NF 
Std* -18.69 -0.71 HIS386: HE2 1 2.176Å PHE209, PHE381 NF 
#
 
Amino Acid, * Std-Standard (Diclofenac), **NF-Not Formed 
An ionic interaction with the side chain residue Arg120 was 
exposed in 1CQE for 5b and in 6COX for 5a and 5b (fig. 4a). 
Interestingly 5b showed both π–cation (ARG120) and π-π 
interactions (HIS90, PHE381 and TYR355) (fig. 4b). Compounds 
5a-h formed strong hydrophobic interactions with nonpolar 
residues in 1CQE like GLN289, ILE523, ILE89, LEU390, and 
LYS211 and in 6COX like ALA516, ILE517, PHE518, VAL349 and 
VAL349 are suggested to increase the binding affinity (fig. 5). 
The results of the ligand docking showed that the binding pocket 
involves the amino acid residues of 1CQE like ASN382, 515; 
ARG49, 83, 120, 433; Asp145; GLU290, 346, 347, 524; PHE91, 
210, 356, 580; GLY214, 354; HIS90, 207, 274, 386, 388, 513; 
ILE46, 89, 137; LYS211, 222, 565; LEU92, 93, 115, 294, 295, 584; 
PRO86, 191, 514; GLN289, 350, 351, 358; SER85, 87, 138, 213, 
516, 579; THR94, 212; VAL 116, 291, 578; TRP100; TYR130, 136, 
385; CYS12, 512; 
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Fig. 3a: The proposed binding mode of 5e into the active binding site of 1CQE with a lowest binding energy of-8.32. Two hydrogen bonds 
(1.855Å&1.856Å) with HIS207 and LYS211 formed with π-π (Non-covalent) interaction 
 
 
Fig. 3b: The proposed binding mode of 5h into the active binding site of 6COX with a lowest binding energy of-19.62. A hydrogen bond 
(2.678Å) with one of a key residue TYR385 formed with π-π (non-covalent) interaction 
 
  
Fig. 4(a, b): Result shows π-cation interaction between the residue AR120 and ligand 5a (1CQE) and 5b (6COX) 
 
  
Fig. 5(a, b): Ligands showing the interaction with the crucial residues in the active site cleft 
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And with the key residues of 6COX like ALA 199, 202, 517, 527; 
ARG120, 513, 222; ASN104, 382; GLN192, 203, 289, 350; GLU346; 
GLY354, 526; HIS90, 207, 366, 386, 388; ILE89, 200, 517, 523; 
LEU531, 350-51, 359, 384, 390-91; LYS211; PHE210, 381, 210, 404, 
518; SER353, 516, 530; THR206, 212; TRP387; TYR348, 355, 385; 
VAL116, 295, 349, 444, 447, 523 as shown in the fig. 5-7. The 
important hydrogen bond forming amino acid residues (table 1&2) 
for 1CQE was ASN515; PHE580; HIS207, 386, 388; ILE137; GLN289; 
THR94; VAL578; TYR 385 and for 6COX it was GLN230; HIS386, 
388; MET522 and TYR355, 385. 
 
  
Fig. 5(a, b): Diclofenac in the binding pocket of 1CQE & 6COX 
 
 
Fig. 6(a, b): Compound 5c in 1CQE and 5e in 6COX binding pockets 
 
 
Fig. 7a: Ribbon shows close residues for the ligands (5e-1CQE) 
 
 
Fig. 7b: Close residues along with one invisible H-bond and π-π (Non-covalent) interaction (5h-6COX) 
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Ligand efficiency (LE) results (table 1&2) clearly showing that 
the action potential of the compounds 5e (-0.72) and 5d (-0.64) 
is high when compare with the standard (-0.63) for COX-1. While 
for COX-2, compounds 5e (-0.81) 5d (-0.79) and 5h (0.98) were 
shown a remarkable Ligand efficiency than the standard (-0.65). 
The RMSD (Root-Mean-Square Deviation) (table 3) was found at 
0.28Å with a low Estimated Inhibition Constant (EIC)–(ki) value 
of 354.99 uM for 5e was the best among all analyzed ligands of 
COX-1 (1CQE). The lowest LBE (least binding energy) was-18.77 
kcal/mol. While the COX-2 (6COX) had an RMSD value of 0.81Å, 
ki value as slow as 389.12 mM for the compound 5h with a LBE 
of-31.94 kcal/mol. The standard Diclofenac had an average 
RMSD of 0.7, ki as low as 20.05 uM and the LBE was-17.46 
kcal/mol. 
 
Table 4: Results of statistical mechanical analysis for best-docked poses in 5(a-h) 
Compounds Binding Energy (kcal/mol)  RMSD Inhibition Constant (ki) 
 COX-1 COX-2 COX-1 COX-2 COX-1 COX-2 
5a -8.23 -6.03 0.88 0.59 46.54 uM 925.51 nM 
5b -8.62 -7.25 0.59 0.3 4.85 uM 480.77 nM 
5c -0.56 -7.03 0.32 0.68 197.20 aM 68.15nM 
5d -16.03 -25.14 0.94 0.62 20.05 uM 44.29 nM 
5e -18.77 -26.69 0.28 0.78 354.99 uM 48.52 nM 
5f -8.16 -9.35 0.59 0.62 139 nM 244.95 nM 
5g -12.02 -8.56 0.81 0.86 529.95 nM 793.99 nM 
5h -8.32 -31.94 0.71 0.81 7.06 uM 389.12 mM 
Std* -16.23 -18.69 0.69 0.71 19.95 uM 20.15 uM 
* Std-Standard (Diclofenac) 
 
In-vitro anti-Inflammatory activity 
As per the results stated in table 4, the maximum values were 
exposed only at the higher concentration. From this, it was 
understood that the anti-inflammatory activity of compounds 5(a-h) 
is dose depended. 
The calculated % inhibition indicates that the compounds 5d and 5h 
showing best activity when is compared to rest compounds while 
compounds 5a and 5e showing a moderate activity. Also the IC50 
values almost equal for 5h with standard Diclofenac. Surprisingly, 
IC50
Antioxidant activity 
 value was a little bit less than the standard for the compound 5d 
indicate its drug efficiency.  
As per the results depicted in Table-5, it was important to 
understand that the antioxidant activity of the compounds 5(a-h) is 
also dose depended. The calculated % inhibition indicates that the 
compounds 5b and 5e showing less activity when is compared to 
rest compounds while the compounds 5d, 5g and 5h showing an 
equal activity when compared to the standard ascorbic acid. 
  
Table 5: In-vitro anti-inflammatory activity of synthesized analogues* 
Compounds % Inhibition mean±SEM R square p-value IC50  
5a 75.98±7.59** 0.9794 0.0103 53.823 
5b 65.31±5.43** 0.9449 0.028 96.331 
5c 63.24±7.41** 0.9237 0.0389 94.385 
5d 82.21±8.33** 0.9836 0.0082 35.429 
5e 80.35±9.23** 0.9461 0.0273 49.983 
5f 73.03±6.46** 0.949 0.0258 67.066 
5g 73.98±7.15** 0.9827 0.0087 63.579 
5h 81.72±7.84** 0.9631 0.0186 35.897 
Diclofenac 87.93±3.59** 0.9752 0.0125 36.363 
Control No inhibition # -- -- -- 
#
 
Distilled water, *Data are expressed as mean±SEM. (N = 3) and the results considered significant when P<0.05 
Table 6: Results of antioxidant activity of synthesized analogues* 
Compounds % inhibition mean±SEM R square p-value IC50 Value 
5a 63.16±09.46** 0.9802 0.0012 75.1634 
5b 52.06±11.88** 0.9009 0.0137 122.972 
5c 63.79±09.27** 0.8624 0.0226 89.6115 
5d 68.92±10.29** 0.9436 0.0058 68.323 
5e 42.65±06.30** 0.9193 0.01 187.274 
5f 62.36±09.81** 0.9802 0.0012 88.575 
5g 68.01±11.42** 0.938 0.0067 69.216 
5h 67.38±08.11** 0.8973 0.0144 56.9444 
Ascorbic acid 70.24±10.54** 0.9526 0.0044 67.9058 
Control No inhibition # -- -- -- 
#
 
Methanol+DPPH, * Data is expressed as mean±SEM. (N = 4) and the results considered significant when P<0.05 
Also the IC50
From all these analyses, except the compounds 5b and 5e rest all 
compounds were shown best antioxidant activities.  
 value found for 5h was lower than the standard, but it 
was almost equal for the compounds 5d and 5f, only a negligible 
variation found for 5a with the standard.  
Statistical results 
As mentioned, statistical analyzes were performed on all the part of 
this study. R2 values and the p-values were calculated and used to 
identify the final results. The value R2 quantifies the goodness of fit 
while a p-value helps to determine the significance of the 
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consequences. In the molecular docking studies, comparing the 
RMSD values, both COX-1 and COX-2 were shown a better result 
than the standard and the compounds are more selective for 
COX-2. For anti-inflammatory the calculated R2 values of the 
standard were 0.9835 which was coinciding with the R2 value of 
compound 5d (0.9836), but compound 5g and 5h had better R2 
values as, 0.9827 and 0.9534. The p-values were significant for 
all the compounds 5(a-h). When comparing the IC 50  values for 
anti-inflammatory studies with the standard (IC 50 -36.36), the 
compound 5d and 5h had a lesser IC 50  value of 35.43 and 35.89. 
It is a remarkable indication that these compounds have the 
capability to be a good drug like the standard. For the 
antioxidant results, the p-values were significant for all the 
compounds 5(a-h). The R2 values of standard (0.9526) closely 
coincided with the compounds 5d (0.9436) and 5g (0.9380), but 
compound 5h had better R2 value (0.8973). IC 50
DISCUSSION 
 value was very 
less for the compound 5h (56.944) when compare the standard 
(67.905) and compounds 5d (68.322) and 5g (69.215).  
(E)-4-arylideneisoquinoline-1,3-diones derivatives obtained by 
condensation of aromatic aldehydes with N-methyl homo 
phthalimide or N-phenyl homo phthalimide in dry chloroform using 
piperidine as a catalyst [22]. Comparing [22] the targeted 
compounds were obtained in this study using an Eco-friendly 
catalyst (Ethanol) with a remarkable purity and high yield when 
compared with the reported. COX-2 inhibition reported by hydrogen 
bonds formed in Arg 120 and Tyr 385, with the free binding energy 
of–1.73 kcal/mol [23]. In this study, ionic interaction with the side 
chain residue Arg120 was found in 1CQE for 5b and in 6COX for 5a 
and 5b. Interestingly 5b showed both π–cation (ARG120) and π-π 
interactions (HIS90, PHE381 and TYR355) with a lowest free 
binding energy of-26.69 kcal/mol. COX (Cyclooxygenase) was 
believed to be expressed constitutively with constant levels in 
individual tissues [24]. Prostaglandin synthesis was believed to 
increase in inflammation because of increased release of precursor 
[25]. COX activity increases in inflammation and this increase can be 
prevented by corticosteroids [26].  
The increased COX2 inhibitory results of our report reflect the 
above-mentioned [24-26] points rightfully. This due to the 
compounds may show anti-corticosteroid activity. Both the COX 
inhibition results and in vitro anti-inflammatory results coincided 
together for the compounds 5h, 5d and 5e. Top three binding energy 
value for COX2 was found as for 5d-25.14 kcal/mol, 5e-26.69 
kcal/mol and for 5h-31.94 kcal/mol. While the top three % 
inhibition mean±SEM was found for 5d 82.21±8.33, 5h 81.72±7.84, 
5e 80.35±9.23. This suggests the need for further in vivo 
investigations. 1,1-Diphenyl-2-picrylhydrazyl (DPPH), a stable free 
radical, accepts hydrogen or an electron to become a durable 
diamagnetic molecule [27]. It is commonly used to test the free 
radical scavenging ability of various samples. Free radical 
scavenging activity is gradually increased with the increase in the 
concentration of the compounds tested and Ascorbic acid (table 6) 
may be due to the dose-dependent activity variations. This is 
incongruent with previous in vitro studies [28, 29]. 
CONCLUSION 
Eight compounds were synthesized and screened for antioxidant 
and anti-inflammatory studies. Docking study of these synthesized 
compounds was also performed. Most of the compounds exhibited 
significant anti-inflammatory and antioxidant activity. Compounds 
5d, 5e, 5g and 5h exhibited more prominent and constituted anti-
inflammatory activity. Compounds 5d, 5g and 5h showed strong 
antioxidant activity in the DPPH tests. From the detailed analysis of 
the results of pharmacological studies, we conclude that the 
synthesized compounds have not only retained but showed 
enhanced anti-inflammatory profile. Also, all the synthesized 
derivatives exhibited significant antioxidant activity. The p-values 
were significant for all the compounds 5(a-h) in both COX-1 and 
COX-2 activities which indicate that all the compounds have 
‘competency’ towards drug-ability for both anti-inflammatory and 
antioxidant especially the compounds 5h<5d<5g<5e can be 
suggested for in vivo. 
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